Seeing double: Designing drugs that target twin cancer proteins Scripps Research scientists used knowledge about a protein to characterize drugs that selectively bind to its twin, or paralog.
September 30, 2024
LA JOLLA, CA Some proteins in the human body are easy to block with a drug; they have an obvious spot in their structure where a drug can fit, like a key in a lock. But other proteins are more difficult to target, with no clear drug-binding sites.
To design a drug that blocks a cancer-related protein, Scripps Research scientists took a hint from the protein's paralog, or twin. Using innovative chemical biology methods, the scientists pinpointed a druggable site on the paralog, and then used that knowledge to characterize drugs that bound to a similar but more difficult to detect spot on its twin. Ultimately, they found drugs that only bound to the protein of interest and not its highly similar sibling.
Their approach, described in Nature Chemical Biology on September 18, 2024, and dubbed paralog hopping, could uncover new binding sites for drugs and inform drug development more broadly, since nearly half of the proteins in human cells including many involved in cancer and autoimmune diseases have such paralogs.
This method may be generally useful in cases where you have paralogs, and you are trying to find a new drug for one of them, says senior author Benjamin Cravatt, PhD, the Norton B. Gilula Chair in Biology and Chemistry at Scripps Research. Being able to target one paralog over another is an important goal in drug development, as two paralogs often have different functions.
Many genes have duplicated throughout evolution, resulting in multiple copies in the human genome. In some cases, copies have evolved slightly different sequences from each other, making their corresponding proteins into paralogs. These protein paralogs remain highly similar in structure and often have redundant or overlapping functions within cells.
In recent years, Cravatt's research team formulated an approach to develop drugs that bind to the amino acid cysteine a protein building block with unique, highly reactive chemical properties. The scientists' method takes advantage of cysteines as an optimal site for drugs to attach to a protein permanently, often inactivating it. However, not all proteins have accessible cysteines. In the cases of paralog pairs, one protein may have a druggable cysteine that the other does not.
We started with this idea that if you know how to drug one protein, you can figure out how to drug its paralog in a similar way, says Yuanjin Zhang, a graduate student at Scripps Research and first author of the new paper.
As a test case, the team tackled the paralog pair known as CCNE1 and CCNE2. Both proteins have been found to be overactive in breast, ovarian and lung cancer. However, scientists suspected that the two proteins play slightly different roles. The team posited that turning off just one protein could make treating some cancers more effective.
It has been difficult, however, to design drugs that target the CCNE1 and CCNE2 proteins to test this hypothesis. Cravatt, Zhang and their colleagues knew that CCNE2 had a druggable cysteine, while CCNE1 did not. If they could identify drugs that bound to the same spot on CCNE1, even in the absence of a cysteine, they suspected the protein would shut off.
The scientists first engineered a cysteine into CCNE1, mimicking the drug-binding spot they had pinpointed in CCNE2. They then leveraged this neo-cysteine to identify drugs that bind to CCNE1. Next, they screened a library of other chemical compounds for the ability to compete with that drug in binding to CCNE1. The team reasoned that some of the compounds that competed for the same spot would bind in ways that did not rely on the cysteine.
Indeed, Cravatt, Zhang and their colleagues discovered multiple compounds that could bind to the same site on CCNE1 even when the cysteine was removed again. Some compounds did not bind to CCNE2. Some also had opposite functions, stabilizing the molecule so that it might be more active than usual, rather than inactivating it. Structural studies revealed that the CCNE1 compounds bind to a cryptic pocket that was not previously known to be druggable.
The team says the approach highlights the importance of screening for drugs in diverse, creative ways.
If we had just screened looking for compounds with a particular function, we would not have identified all of these various functional molecules, and if we had just looked at the structure of CCNE1, we would not have found this binding pocket at all, says Zhang.
More research is needed to discover whether the new compounds have potential utility in treating cancer or other diseases in which CCNE1 plays a role. Next, the scientists plan to apply their paralog-hopping method to other pairs of proteins important for tumorigenesis.
In addition to Cravatt and Zhang, authors of the study, An allosteric cyclin E-CDK2 site mapped by paralog hopping with covalent probes, include Zhonglin Liu, Sang Joon Won, Divya Bezwada and Bruno Melillo of Scripps Research; and Marsha Hirschi, Oleg Brodsky, Eric Johnson, Asako Nagata, Matthew D. Petroski, Jaimeen D. Majmudar, Sherry Niessen, Todd VanArsdale, Adam M. Gilbert, Matthew M. Hayward, Al E. Stewart and Andrew R. Nager of Pfizer, Inc.
This work was supported by funding from the National Cancer Institute (R35 CA231991) and Pfizer.
Chemistry Cravatt, Benjamin
North America Stories
20/05/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
20/05/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
20/05/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
19/05/2026
Cisco and the USGA have announced a multiyear extension of their partnership, which began in 2018. Cisco serves as the Official Technology Partner of the USGA, ...
19/05/2026
Urban Edge Network (UEN), a streaming platform for NAIA sports, has announced a partnership with Spiideo to provide streaming and production tools to UEN's ...
19/05/2026
Warner Bros. Discovery (WBD) will provide live coverage of all 900 Roland-Garros matches across its platforms beginning with qualifiers on May 18. In Europe, 21...
19/05/2026
Tubi, Fox Corporation's free streaming service, has announced the launch of the FIFA World Cup 2026 FOX Hub, a dedicated destination for World Cup programmi...
19/05/2026
Telef nica, in collaboration with Sony, has conducted a 5G connectivity trial at the Movistar Arena in Spain using the 26 GHz millimetre wave (mmWave) band. The...
19/05/2026
Ross Production Services (RPS) has installed a Calrec Argo M console into its new Hypermax-1 remote production truck, replacing one of three Argo S consoles pre...
19/05/2026
Panasonic Projector and Display Corporation has announced the acquisition of 100% of the shares of UK-based media technology company Hive Media Control Ltd. (HI...
19/05/2026
Globecast has announced the completion of a nine-month renovation of its Singapore facility, converting it from a traditional linear broadcast operation into a ...
19/05/2026
Grass Valley has announced a three-year enterprise agreement with Phoenix Broadc...
19/05/2026
Bitmovin has announced that Watch Brasil, a streaming platform operating across Brazil and Europe since 2018, has replaced its legacy systems with Bitmovin'...
19/05/2026
Ateme has announced the migration of Dish Home Nepal's Nepal Premier League (NPL) streaming infrastructure to Ateme's TITAN Live solution deployed on Ak...
19/05/2026
CMSI provided workflow, media management, and HDR support for ESPN during coverage of the NCAA Gymnastics Semifinals and Championships. The company supported fi...
19/05/2026
In advance of this year's Sports Emmy Awards, SVG is taking a deep dive into the six production-technologies nominated for this year's George Wensel Tec...
19/05/2026
In advance of this year's Sports Emmy Awards, SVG is taking a deep dive into the six production-technologies nominated for this year's George Wensel Tec...
19/05/2026
Featuring a fully IP infrastructure, Supershooter 11 is intended for large-scale events. Enabling remote and distributed workflows, Supershooter 65 joins the RE...
19/05/2026
By Jessica Herndon
The line wrapped around the building outside Denver's La...
19/05/2026
When all companies in the market are allowed to compete under the same set of ru...
19/05/2026
Battle-proven technology withstands electronic warfare threats across air, maritime surface and subsea domains....
19/05/2026
WESCAM MX-Series EO/IR systems provide high-precision targeting across domains, including counter-UAS applications...
19/05/2026
Champaign, IL - March 16, 2026 Cobalt Digital, the leading designer and manufa...
19/05/2026
CHAMPAIGN, Ill. April 16, 2026 - Cobalt Digital today announced a partnership ...
19/05/2026
Las Vegas - April 18, 2026 Cobalt Digital, the leading designer and manufactur...
19/05/2026
LAS VEGAS April 18, 2026 - Advanced HDR by Technicolor and Cobalt Digital are ...
19/05/2026
LAS VEGAS - May 4, 2026 - Cobalt Digital, the leading designer and manufacturer of signal processing products, and a founding partner in the openGear initiativ...
19/05/2026
London - 11 May 2026 Cobalt Digital, the leading designer and manufacturer of award-winning signal processing products, and a founding partner in the openGear...
19/05/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
19/05/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
19/05/2026
Grass Valley has entered into a three-year enterprise agreement with Phoenix Broadcast Solutions as the Singapore-based company expands its live production oper...
19/05/2026
Clear-Com supported Musikal Perahu Kertas, a large-scale musical theater production in Indonesia adapted from the acclaimed novel by Dee Lestari, through the d...
19/05/2026
Actus Digital, a LiveU company, and a leading provider of intelligent media monitoring and broadcast compliance platforms, announced today that METEO CONSULT ha...
19/05/2026
Globecast, a leading provider of managed services for the broadcast and media industry, today announced the completion of a major renovation of its Singapore fa...
19/05/2026
Following a major upgrade to its Connecticut remote production centre with the installation of three 60-fader Argo S consoles in 2023, RPS has switched one of t...
19/05/2026
PlayBox Technology today announced the launch of Celebro Play, a browser-based media orchestration platform designed specifically for broadcast facilities and p...
19/05/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
19/05/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
19/05/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
19/05/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
19/05/2026
LYNX Technik, provider of modular signal processing solutions for broadcast, post, and professional AV will showcase its latest signal processing solutions at B...
19/05/2026
Media Links, a leading developer and manufacturer of IP media transport solutions, has announced the integration of its Xscend platform with Skyline Communicat...
19/05/2026
Collaboration expands regional partner ecosystem as Media Links showcases IP media transport solutions on stand 4M4-4 and alongside Clearcast Asia on stand
Me...
19/05/2026
Company Highlights Labor-Saving Control and Custom Branding Opportunities Designed to Increase Integrator Profitability
LynTec, a leading manufacturer of ele...
19/05/2026
Mago Studio Moves AI Video Beyond Prompts with New Production-Focused Tools
Brie Clayton May 18, 2026
0 Comments
New Capabilities Bring Controllable, ...
19/05/2026
It May be Time to Stop and Take an AI Breather
Brie Clayton May 19, 2026
0 Comments
If the rock you stay on starts to roll, jump clean. Or you'll...
19/05/2026
At this year's Google I/O conference, NVIDIA and Google Cloud are accelerating the work of more than 100,000 developers in the companies' joint develope...
19/05/2026
Back to All News
Netflix Unveils the Trailer for RAFA, the Documentary Series A...
19/05/2026
Back to All News
Netflix Expands Consumer Products Footprint with Strategic Con...
Seeing double: Designing drugs that target twin cancer proteins Scripps Research scientists used knowledge about a protein to characterize drugs that selectively bind to its twin, or paralog.
